Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 November 2021 | Story Leonie Bolleurs | Photo Supplied
With her talk on ‘Breaking the walls of darkness’, Emmie Chiyindiko came in second out of the 74 pitches presented at the recent Falling Walls Science Summit.

“I need you to take a moment and imagine trying to do everything that you do every day … without reliable energy. Or I’ll ask you this … How far would you walk to charge your phone if you didn’t have electricity? Would you walk for hours? Kilometres?”

“Well, that’s what millions of people in sub-Saharan Africa do daily to charge their phones. One billion people globally don’t have access to electricity in their homes and in sub-Saharan Africa, more than half of the population remains in the dark.”

This was the introduction to Emmie Chiyindiko’s talk at the recent Falling Walls Science Summit earlier this month. Emmie, who is a PhD student in Chemistry at the University of the Free State (UFS), came in second out of the 74 pitches presented with her talk on ‘Breaking the walls of darkness’ in the ‘Breakthrough of the year in the emerging talents category’.

Falling Walls Lab is a world-class pitching competition, networking forum, and steppingstone that brings together a diverse and interdisciplinary pool of students, researchers, and early-career professionals by providing a stage for breakthrough ideas, both globally and locally. 

Emmie, who sees getting out of bed every morning as just another opportunity to “be the exceptional young black female scientist that I am”, won the local Falling Walls Lab in Cape Town in October, which resulted in her going through to the finals in Berlin. She plans to host the Falling Walls Lab in Zimbabwe, her homeland, next year. 

This innovator and science communicator, whose work has been covered in Forbes Science, News24, and the Sunday Times, among others, refers to her obtaining second place on the international stage for her research as “a tremendous achievement and a new height in my science communication career. That level of recognition from the world leaders in science, technology, and science engagement cannot be overstated”.

Ending energy poverty

She believes Sustainable Development Goal 7 – leaving no one behind and eradicating global poverty – must be preceded by intentional efforts to end energy poverty. “My research on dye-sensitised solar cells (DSSC) with special metal complexes is among the most interesting alternatives to conventional solar cells.”

Emmie explains: “The design of the cells is inspired by photosynthesis – that good old process plants use to transform sunlight into energy via chlorophyll. Instead of a leaf, the cells start with a porous, transparent film of eco-friendly titanium dioxide nanoparticles. The film is also coated with a range of different dyes that absorb scattered sunlight and fluorescent light. When sunlight hits, it excites the electrons in the dye, creating an endless supply of energy. 

The bright side of this research is that there are several benefits to this invention. It produces energy that is cheap, reliable, and relatively simple and inexpensive to produce. Emmie adds: “These next-generation cells also work impeccably in low-light and non-direct sunlight conditions, providing all-year-round energy with no disruptions. DSSC is also three times cheaper than conventional cells and produces 40% more energy.”

Improving livelihoods 

She continues: “It does not degrade in sunlight over time as do other thin-film cells, making the cells last longer, and requiring less frequent replacement. DSSCs are also mechanically strong, because they are made of lightweight materials and do not require special protection from rain or abrasive objects.”

Emmie has proven that solutions to our current energy situation are available. “We are on the cusp of an energy revolution, and we must act now. Solutions are available, and if we do not seize them during a time of crisis, when will we?”

She believes that creating technology like this can end the energy crisis and improve livelihoods. “Billions of people simply lack enough energy to build a better life. Affordable, abundant, and reliable energy can go a long way to store food, power life-saving medical equipment, and run trains and factories. It can help communities to grow and prosper and to access opportunity and dignity. Societies where people have access to energy have lower childhood mortality, a higher life expectancy, they eat better and drink cleaner water, and have a better literacy rate.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept